Darlene Dobkowski, MA | Contributors

Venclexta With Velcade and Dexamethasone May Improve Progression-Free Survival in Relapsed or Refractory Multiple Myeloma

December 04, 2020

The phase 3 trial found that this treatment improves progression-free survival (PFS) during 18.7 months of follow-up, although patients treated with Venclexta (venetoclax) a had increased mortality rates compared with those treated with placebo.